BusinessSummit Therapeutics to Present at the Canaccord Genuity Growth ConferenceBy Nasdaq OMXAug 3, 2017, 11:00 AM UTC
BusinessSummit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressBy Nasdaq OMXJun 22, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressBy Nasdaq OMXJun 14, 2017, 11:00 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMDBy Nasdaq OMXMar 27, 2017, 11:02 AM UTC
